Table 1.
CD133 and ALDH1 expression in liposarcoma patient samples.
| Diagnosis | Tumour site | Age | Pre-treatment | Grade | CD133 | ALDH1 | |
|---|---|---|---|---|---|---|---|
| Cytoplasm | Nucleus | ||||||
| Well-diff. | Retroperitoneal | 36 | No treatment | 1 | 0 | 3 | 3 |
| Well-diff. | Retroperitoneal | 57 | No treatment | 2 | 0 | 3 | 3 |
| Myx/roundcell | Thigh | 41 | No treatment | 3 | 0 | 3 | 3 |
| Myx/roundcell | Thigh | 79 | Chemotherapy | 4 | 0 | 3 | 3 |
| De-diff. | Thigh | 79 | No treatment | 4 | 0 | 3 | 3 |
| De-diff. | Retroperitoneal | 60 | No treatment | 4 | 0 | 1 | 1 |
| Well-diff. Comp * | Retroperitoneal | 64 | No treatment | 0 | 3 | 3 | |
| De-diff. Comp* | Retroperitoneal | 64 | No treatment | 4 | 0 | 3 | 3 |
| Pleomorphic | Truncus | 67 | No treatment | 4 | 0 | 3 | 3 |
| Pleomorphic | Retroperitoneal | 58 | No treatment | 4 | 0 | 3 | 2 |
| Well-diff. | Leg | 31 | No treatment | 1 | 0 | 2 | 2 |
Ten liposarcomas diagnosed as well-differentiated (well-diff.), myxoid/roundcelled (myx/roundcell), de-differenitated (de-diff) or pleomorphic were included in the analyses. Tumour location, patient age, treatment prior to sample collection and tumour grade are also displayed. CD133 and ALDH1 expression was scored as follows: 0 = negative, 1 = less than 10% of the tumour cells scored positive, 2 = 10-50% of the rumour cells scored positive, 3 = more than 50% of the tumour cells scored positive. *For one of the tumors, a de-differentiated and a well-differentiated component was analysed.